Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Prostatic Neoplasms 3Recurrence 2Small Cell Lung Carcinoma 1Metastatic Castration-Resistant Prostate Cancer 1Lymphoma, Follicular 1Adenocarcinoma 1

Interventions

Etoposide 30Carboplatin 29atezolizumab 17durvalumab 16Cisplatin 14Topotecan 11Specimen Handling 9PM 01183 9Magnetic Resonance Spectroscopy 7pembrolizumab 6olaparib 5berzosertib 4anlotinib 4Radiotherapy 4Nivolumab 4Irinotecan 4Drug Therapy 4tremelimumab 3toripalimab 3tislelizumab 3Paclitaxel 3Injections 3Docetaxel 3Biopsy 3Bevacizumab 3AMG 757 3sacituzumab govitecan 2monalizumab 2cabozantinib 2Temozolomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × PF06821497 × 90 days × Clear all
NCT03460977 2026-06-05

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Pfizer

Phase 1 Recruiting
453 enrolled
LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡